Silver Book Fact

Use of a monocolonal antibody with adjuvant chemotherapy in HER2+ individuals with operable cancer was associated with a 33 percent reduction in risk of death.

Romond E, Perez E, Bryant J, Suman V, et al. Tastuzumab Plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer. NEJM. 2005; 353: 1673-84. http://www.nejm.org/doi/full/10.1056/NEJMoa052122

Reference

Title
Tastuzumab Plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer
Publication
NEJM
Publication Date
2005
Authors
Romond E, Perez E, Bryant J, Suman V, et al.
Pages
1673-84
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • According to the Pharmaceutical Research and Manufacturers of America, a medicine currently in development may delay the worsening of liver cancer. The medicine is an oral signal transduction inhibitor…  
  • Drugs like bevacizumab- designed to impede the growth of blood vessels and tumors- can cost more than $100,000 per patient.   
  • According to the Pharmaceutical Research and Manufacturers of America, a number of vaccines are being studied that would cause the body’s own immune system to fight cancer after it has…  
  • Since 1980, 83 percent of gains in life expectancy for cancer patients have been attributable to new treatments.  
  • As of July 2014, 18 anticancer drugs received FDA approval after being designated breakthrough therapies.